Health Trials

Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3

ConditionRenal Insufficiency, Chronic
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorThe First Affiliated Hospital of Dalian Medical University

About this trial

This is a multicentre prospective, randomized, double-blind and imitation, positive-drug parallel controlled clinical trail. The objective of this study is to evaluate the efficacy and safety of Huaiqihuang Granule in patients with CKD stage 3 primary glomerulonephritis.

Eligibility criteria

Qualifiers

Diagnosed as primary glomerulonephritis by renal biopsy

Male or female, 18≤age≤65

Blood pressure can be effectively controlled at or below 140/90mmHg

30mL/（min.1.73m2）≤ eGFR<60mL/（min.1.73m2）

Disqualifiers

Diagnosed as secondary glomerulonephritis

Exposure to corticosteroids, immunosuppressors, tripterygium glycosides, ARBs or ACEIs, without a two weeks washout period

Blood pressure < 90/60 mmHg

Serum potassium > 5.5 mmol/L

Trial design

Treatments tested in this trial

  • Huaiqihuang granules
  • Valsartan capsule

Treatment groups

466 Participants
are divided into 2 treatment groups

Locations

34
Beijing Hospital100005, BeijingBeijing Municipality, China
Lanzhou University Second Hospital730030, LanzhouGansu, China
The First Affiliated Hospital of Guangxi Medical University530021, NanningGuangxi, China
The Fourth Hospital of Hebei Medical University050000, ShijiazhuangHebei, China

Sponsors and collaborators

The First Affiliated Hospital of Dalian Medical University

Lead sponsor

Huazhong University of Science and Technology

Collaborator

LinkDoc Technology (Beijing) Co. Ltd.

Collaborator

Source ClinicalTrials.gov